Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by INVENTIVA

< Previous 1 2 Next >
Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3
From INVENTIVA
Via GlobeNewswire
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
From INVENTIVA
Via GlobeNewswire
Inventiva draws down the second tranche of €25 million under existing Finance Contract with the European Investment Bank
From INVENTIVA
Via GlobeNewswire
Inventiva announces the randomization of the first patient in China in the NATiV3 clinical trial and provides an update on its clinical development program
From INVENTIVA
Via GlobeNewswire
Inventiva announces the positive recommendation of the third DMC of the Phase III clinical trial with lanifibranor in patients with NASH
From INVENTIVA
Via GlobeNewswire
Inventiva reports 2023 Third Quarter Financial Information¹
From INVENTIVA
Via GlobeNewswire
Inventiva announces a late breaker abstract and two additional abstracts on its lead compound, lanifibranor, at the AASLD The Liver Meeting® 2023
From INVENTIVA
Via GlobeNewswire
Inventiva reports its 2023 first-half financial results and provides a corporate update
From INVENTIVA
Via GlobeNewswire
Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea
From INVENTIVA
Via GlobeNewswire
Inventiva announces a financing of approximately €35.7 million from new and existing investors, consisting of a €30.6 million reserved capital increase and a €5.1 million issuance of royalty certificates
From INVENTIVA
Via GlobeNewswire
Correction: Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update
From INVENTIVA
Via GlobeNewswire
Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update
From INVENTIVA
Via GlobeNewswire
Inventiva announces the presentation of a scientific abstract at the 83rd Scientific Sessions of the American Diabetes Association
From INVENTIVA
Via GlobeNewswire
Inventiva announces positive topline results from the investigator-initiated Phase II clinical trial evaluating lanifibranor in patients with T2D and NAFLD
From INVENTIVA
Via GlobeNewswire
Inventiva and Echosens launch joint initiative to increase NASH awareness and access to screening for at-risk patients
From INVENTIVA
Via GlobeNewswire
Inventiva announces five scientific presentations at the EASL International Liver Congress™ 2023
From INVENTIVA
Via GlobeNewswire
Results of the votes of the Combined Shareholders’ General Meeting of May 25, 2023
From INVENTIVA
Via GlobeNewswire
Inventiva announces that its partner Sino Biopharm received IND approval from the NMPA to initiate clinical trial with lanifibranor in China
From INVENTIVA
Via GlobeNewswire
Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 25 May 2023
From INVENTIVA
Via GlobeNewswire
Inventiva reports 2023 First Quarter Financial Information¹ and provides a corporate update
From INVENTIVA
Via GlobeNewswire
Inventiva announces filing of its 2022 Universal Registration Document and 2022 Annual Report on Form 20-F
From INVENTIVA
Via GlobeNewswire
Inventiva reports its 2022 full-year results
From INVENTIVA
Via GlobeNewswire
Inventiva announces the schedule of publication and presentation of its 2022 Full-Year Financial Results
From INVENTIVA
Via GlobeNewswire
Correction: Inventiva reports preliminary financial results for Full-Year 2022¹
From INVENTIVA
Via GlobeNewswire
Inventiva reports preliminary financial results for Full-Year 2022¹
From INVENTIVA
Via GlobeNewswire
Inventiva announces changes to the clinical development of lanifibranor, including plans for a new Phase III trial in patients with NASH and compensated cirrhosis
From INVENTIVA
Via GlobeNewswire
Inventiva draws down €25 million tranche under Finance Contract with the European Investment Bank
From INVENTIVA
Via GlobeNewswire
Inventiva secures a new patent expanding the IP protection of its lead product candidate lanifibranor in the US
From INVENTIVA
Via GlobeNewswire
Inventiva announces a new Director of the Board of Directors
From INVENTIVA
Via GlobeNewswire
Inventiva reports 2022 Third Quarter Financial Information¹
From INVENTIVA
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.